1 / 8

My Personal Thoughts on SMARTs

My Personal Thoughts on SMARTs. Christy Chuang-Stein Pfizer Inc The views expressed here are completely my own. They do not reflect those of Pfizer’s or of any other group I am associated with. 6 th UPenn Conference Statistical Issues in Clinical Trials. SMART.

norina
Télécharger la présentation

My Personal Thoughts on SMARTs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. My Personal Thoughts on SMARTs Christy Chuang-Stein Pfizer Inc The views expressed here are completely my own. They do not reflect those of Pfizer’s or of any other group I am associated with. 6th UPenn Conference Statistical Issues in Clinical Trials

  2. SMART • Intuitive, interesting and innovative • Some pharma companies have employed certain aspects of the SMART concept. • The SMART idea is being explored to determine the strategies for a development program by an academic-industry subteam of the Adaptive Design Working Group.

  3. CATIE • Clinical Antipsychotic Trials of Intervention Effectiveness (in patients with chronic schizophrenia) • The largest, longest, and most comprehensive independent trial to examine existing therapies for schizophrenia, conducted between Jan 2001 and Dec 2004 • Funded by the National Institute of Mental Health with drugs donated by the manufacturers in identical-looking capsules • The objective was to determine which medications provided the best treatment for schizophrenia. • 1,493 subjects were initially randomized to one of five drugs. Patients were to receive the drug for 18 months. 74% of patients discontinued the initial treatment early.

  4. R Phase I Olanzapine Quetiapine Risperidone Ziprasidone Perphenazine Atypical antipsychotics (2nd generation) Responded Phase II (543 patients) Discontinued - lack of efficacy Discontinued - side effect Continue R R Clozapine A diff atypical Ziprasidone A diff atypical

  5. A Possible Application: Targeted Therapy If respond, continue New TT If fail, receive SOC R If respond, continue SOC If respond, continue New TT If fail, receive SOC If fail Among patients with the targeted characteristics R If respond, continue SOC, 2nd line New TT If fail R SOC, 3rd line

  6. Another Possible Application: POC Enrichment After washout Responders New candidate Enrichment : likely responders Placebo R A marketed product in the same class Non-responders New candidate Enrichment: non-responders R Placebo FDA draft guidance: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, issued in Dec 2012.

  7. SMART Concept at the Program Level • Consider Phase II and Phase III as two contiguous stages of the development program. We want to choose the best strategy for each stage. • We know the type of information we want to have at the end of Phase III. Can we back-engineer to identify the optimal dose-finding strategy for Phase II? • An academe-industry subteam has been looking at this for the past 2 years. Technical solutions proved to be challenging. • The subteam is part of the “Adaptive Program” workgroup. The latter is part of an extensive academe- industry-government “Adaptive Design Working Group”. ADWG has been active since 2005.

  8. Final Thoughts • Pharmaceutical industry has always been looking for better and more efficient ways to develop products, maintaining high quality for the evidential basis under the constraints of time and cost. • CATIE is unique in its scope and objective (and 43 million USD, 10 years ago). Many comparisons between active treatments are being carried out either indirectly or based on non-RCT data sources. • Forming collaboration and partnerships is a great way forward to pilot-test the concept and generate interests among different stakeholders.

More Related